Type 1 Diabetes Mellitus Clinical Trial
Official title:
Nocturnal Closed-Loop Control Using An ePID (Enhanced Proportional Integral Derivative) Algorithm On An Android Platform With Remote Monitoring In A Closely Monitored Camp Setting: The OCL Camp Study
Verified date | October 2019 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To test the function and safety of the Medtronic Overnight Closed Loop (OCL) System in a
closely monitored 12 hour overnight inpatient study. Once the safety of the device has been
validated we will move the study to an outpatient diabetes camp setting. The camp setting
will allow us to obtain pilot efficacy and safety data in a "real-life" environment.
We plan to compare the subject control nights to the subject nights on the OCL system to
assess the percent of sensor glucose readings in the target range of 70-150 mg/dl. Based on
previous research, we anticipate that the use of the OCL system will contribute to a greater
percentage of sensor glucose readings in the target range.
Status | Completed |
Enrollment | 37 |
Est. completion date | August 3, 2013 |
Est. primary completion date | August 3, 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 10 Years to 35 Years |
Eligibility |
Inclusion Criteria: To be eligible for the study, a subject must meet the following criteria: - Clinical diagnosis of type 1 diabetes and using daily insulin therapy for at least one year and a Medtronic insulin infusion pump for at least 3 months The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required. - Age 10.0 - 35 years Exclusion Criteria: The presence of any of the following is an exclusion for the study: - Diabetic ketoacidosis in the past month - Hypoglycemic seizure or loss of consciousness in the past 3 months - History of seizure disorder (except for hypoglycemic seizure) - History of any heart disease including coronary artery disease, heart failure, or arrhythmias - Cystic fibrosis - Current use of oral/inhaled glucocorticoids, beta-blockers or other medications, which in the judgment of the investigator would be a contraindication to participation in the study. - History of ongoing renal disease (other than microalbuminuria). - Medical or psychiatric condition that in the judgment of the investigator might interfere with the completion of the protocol such as: - Inpatient psychiatric treatment in the past 6 months - Uncontrolled adrenal disorder - Abuse of alcohol - Pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | Stanford University | Stanford | California |
Lead Sponsor | Collaborator |
---|---|
Bruce A. Buckingham |
United States,
Ly TT, Keenan DB, Roy A, Han J, Grosman B, Cantwell M, Kurtz N, von Eyben R, Clinton P, Wilson DM, Buckingham BA. Automated Overnight Closed-Loop Control Using a Proportional-Integral-Derivative Algorithm with Insulin Feedback in Children and Adolescents — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Target Sensor Glucose 70-150 mg/dl | Compared to control nights, the percent of time in the target range of 70-150 mg/dl according to sensor glucose readings. | Approximately 12 hours | |
Primary | Target Sensor Glucose 70-150 mg/dl | Percent of time in the target range of 70-150 mg/dl according to sensor glucose readings. | Approximately 12 hours | |
Secondary | Target Sensor Glucose 70-180 mg/dl | Compared to control nights, the percent of time in the target range of 70-180 mg/dl according to sensor glucose readings. | Approximately 12 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02596204 -
Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring
|
N/A | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A |